NASDAQ:DRRX DURECT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.53 -0.05 (-8.64%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$0.52▼$0.6050-Day Range$0.38▼$0.6452-Week Range$0.36▼$1.84Volume23.47 million shsAverage Volume1.02 million shsMarket Capitalization$120.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock Forecast (MarketRank)Overall MarketRank™1.58 out of 5 starsMedical Sector974th out of 1,417 stocksPharmaceutical Preparations Industry484th out of 675 stocksAnalyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for DURECT. Previous Next 4.8 Community Rank Outperform VotesDURECT has received 310 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDURECT has received 120 “underperform” votes. (Add your “underperform” vote.)Community SentimentDURECT has received 72.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote “Outperform” if you believe DRRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have bought more of their company's stock than they have sold. Specifically, they have bought $73,686.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of DURECT is held by insiders.Percentage Held by Institutions50.60% of the stock of DURECT is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($0.19) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DURECT (NASDAQ:DRRX)DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Stock News HeadlinesJune 18, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In DURECT Corporation's (NASDAQ:DRRX) Shares?June 18, 2022 | americanbankingnews.comShort Interest in DURECT Co. (NASDAQ:DRRX) Declines By 14.5%June 10, 2022 | americanbankingnews.comDURECT Co. (NASDAQ:DRRX) Expected to Post FY2023 Earnings of ($0.23) Per ShareJune 8, 2022 | americanbankingnews.comDURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.comMay 20, 2022 | benzinga.comExecutives Buy Around $17M Of 5 Penny Stocks - Benzinga - BenzingaMay 18, 2022 | finance.yahoo.comDURECT Corporation to Present at the H.C. Wainwright Global Investment ConferenceMay 8, 2022 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo FinanceMay 8, 2022 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 6, 2022 | finance.yahoo.comDURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs - Yahoo FinanceMay 4, 2022 | finance.yahoo.comQuinStreet (QNST) Misses Q3 Earnings and Revenue Estimates - Yahoo FinanceMay 4, 2022 | finance.yahoo.comStaar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates - Yahoo FinanceApril 27, 2022 | finance.yahoo.comDURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4March 24, 2022 | nasdaq.comIs Most-Watched Stock Tesla, Inc. (TSLA) Worth Betting on Now? - NasdaqSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees79Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/26/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36.26 million Net Margins-270.27% Pretax Margin-270.27% Return on Equity-60.89% Return on Assets-39.26% Debt Debt-to-Equity Ratio0.44 Current Ratio7.83 Quick Ratio7.60 Sales & Book Value Annual Sales$13.98 million Price / Sales8.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book2.12Miscellaneous Outstanding Shares227,760,000Free Float215,920,000Market Cap$120.46 million OptionableOptionable Beta1.45 DURECT Frequently Asked Questions Should I buy or sell DURECT stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DURECT stock. View analyst ratings for DURECT or view top-rated stocks. How has DURECT's stock price performed in 2022? DURECT's stock was trading at $0.9859 on January 1st, 2022. Since then, DRRX shares have decreased by 46.4% and is now trading at $0.5289. View the best growth stocks for 2022 here. Are investors shorting DURECT? DURECT saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 11,290,000 shares, a decrease of 14.5% from the May 15th total of 13,200,000 shares. Based on an average trading volume of 917,400 shares, the short-interest ratio is currently 12.3 days. Approximately 5.0% of the shares of the company are sold short. View DURECT's Short Interest. When is DURECT's next earnings date? DURECT is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for DURECT. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) posted its earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The specialty pharmaceutical company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $2.43 million. DURECT had a negative net margin of 270.27% and a negative trailing twelve-month return on equity of 60.89%. During the same quarter last year, the firm posted ($0.05) earnings per share. View DURECT's earnings history. Who are DURECT's key executives? DURECT's management team includes the following people: Dr. James E. Brown D.V.M., Co-Founder, CEO, Pres & Director (Age 65, Pay $859.68k)Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 65, Pay $436.99k)Dr. Norman L. Sussman M.D., Chief Medical Officer (Age 69, Pay $570.32k)Ms. Jian Li M.B.A., Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec. (Age 52)Dr. Andrew R. Miksztal, VP of Pharmaceutical R&D and Principal ScientistMr. Steve Helmer J.D., VP & Chief Patent CounselDr. WeiQi Lin, Exec. VP of R&D and Principal ScientistDr. Su Il Yum Ph.D., Exec. Officer (Age 83) Who are some of DURECT's key competitors? Some companies that are related to DURECT include Radius Health (RDUS), Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Altimmune (ALT), Protagonist Therapeutics (PTGX), Imago BioSciences (IMGO), Centessa Pharmaceuticals (CNTA), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), Edgewise Therapeutics (EWTX), Arbutus Biopharma (ABUS), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR) and Tango Therapeutics (TNGX). View all of DRRX's competitors. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." Who are DURECT's major shareholders? DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Ingalls & Snyder LLC (3.18%), State Street Corp (1.75%), CM Management LLC (1.55%), Renaissance Technologies LLC (1.54%) and Beirne Wealth Consulting Services LLC (1.21%). Company insiders that own DURECT stock include Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito. View institutional ownership trends for DURECT. Which institutional investors are selling DURECT stock? DRRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Ingalls & Snyder LLC, Goldman Sachs Group Inc., and Simplex Trading LLC. Company insiders that have sold DURECT company stock in the last two years include Judy R Joice, and Lp Bleichroeder. View insider buying and selling activity for DURECT or view top insider-selling stocks. Which institutional investors are buying DURECT stock? DRRX stock was bought by a variety of institutional investors in the last quarter, including CM Management LLC, Renaissance Technologies LLC, Beirne Wealth Consulting Services LLC, Connor Clark & Lunn Investment Management Ltd., Eqis Capital Management Inc., Gagnon Securities LLC, State Street Corp, and Tobias Financial Advisors Inc.. Company insiders that have bought DURECT stock in the last two years include Gail M Farfel, Judith J Robertson, Mohammad Azab, and Simon X Benito. View insider buying and selling activity for DURECT or or view top insider-buying stocks. How do I buy shares of DURECT? Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $0.53. How much money does DURECT make? DURECT (NASDAQ:DRRX) has a market capitalization of $120.46 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36.26 million in net income (profit) each year or ($0.16) on an earnings per share basis. How many employees does DURECT have? DURECT employs 79 workers across the globe. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for DURECT is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at [email protected], or via fax at 408-777-3577. This page (NASDAQ:DRRX) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here